Made in Italy pharmaceuticals will be able to be competitive if they reach 2 billion euros in turnover and are able to concentrate on individual therapeutic areas and operate with a global reach. This was reported by a study by Enter, the Bocconi Entrepreneurship Research Center, carried out with the contribution of Farmindustria, which examined 11 groups with Italian capital. In favor of medium-sized companies, the expiry in a few years of drug patents that generate 137 billion dollars in annual turnover and the loss of approximately 50% of the value of sales. However, the weak point of the sector concerns the inadequacy of tax incentives for R&D, which are increasingly decisive also in the localization strategy of investments by multinationals. Sergio Dompè, President of Farmindustria, reiterates: "let's not miss out on excellence".
la Repubblica Affari & Finanza Pag.12 – 22/03/2010 
